Shigenori E Nagai
7PUBLICATIONS
25CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando
|Feb 11, 2026
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.Hiroko Masuda, Shigenori E Nagai, Masaya Hattori
|Apr 05, 2025
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami
|Apr 20, 2024
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori
|Oct 07, 2023
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.Mitsuo Terada, Aki Ito, Yuichiro Kikawa
Pageof 2
Frequent Collaborators
6 joint publications
Norikazu Masuda
3 joint publications
Nobuyoshi Kosaka
2 joint publications
Hiroyuki Yasojima
2 joint publications
Hiroko Bando
2 joint publications
Masakazu Toi
2 joint publications
Rikiya Nakamura
1 joint publications
Kentaro Tajima
1 joint publications
Takashi Yamanaka
1 joint publications
Tetsuro Sasada
1 joint publications
Masato Takahashi
